Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . (Exact name of registrant as specified in its charter) Utah 87-0447695 (State or other jurisdiction of incorporation or organization) (IRS Employe ...

Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical +1-801-432-2864 +1-443-213-0509 Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare sarah.comstock@merit.com mike.piccinino@icrhealthcare.com FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR GUIDANCE First Quarter Highlights† Exhibit 99.1 † Comparisons above are calculated for the current quarter compared with the first quarter of 2024, unless otherwise specified. Amounts stated in this release are ...

Core Insights - Merit Medical Systems, Inc. reported a revenue of $355.4 million for Q1 2025, reflecting a 9.8% increase compared to Q1 2024 [4][6] - The company achieved a constant currency revenue growth of 10.9% and an organic constant currency revenue increase of 6.0% year-over-year [4][6] - Non-GAAP earnings per share (EPS) rose by 14.8% to $0.86, while GAAP EPS increased by 2.0% to $0.49 [6][9] Financial Performance - The GAAP operating margin improved to 11.5% from 11.1% in the prior year, while the non-GAAP operating margin increased to 19.3% from 17.0% [6][8] - Free cash flow generation was reported at $19.5 million, down 20.5% compared to the previous year [6] - The company’s GAAP net income for Q1 2025 was $30.1 million, compared to $28.2 million in Q1 2024 [9] Revenue Breakdown - Revenue by segment showed significant growth in the Cardiovascular segment, with a 10.6% increase in Cardiac Intervention and a 20.5% increase in OEM [5] - The Endoscopy segment also saw substantial growth, with revenue increasing by 64.2% [7] - Total revenue for the Cardiovascular segment was $338.7 million, up 8.1% year-over-year [5] Guidance and Outlook - The company reaffirmed its total revenue guidance for 2025, projecting revenues between $1.470 billion and $1.490 billion, representing an 8% to 10% year-over-year increase [11] - Non-GAAP EPS guidance was updated to reflect stronger-than-expected Q1 results, now projected between $3.29 and $3.42 [11] - The company anticipates continued stable constant currency growth despite potential impacts from trade policies [5][11] Balance Sheet Highlights - As of March 31, 2025, Merit had cash and cash equivalents of $395.5 million, an increase from $376.7 million at the end of 2024 [10] - Total debt obligations remained stable at $747.5 million [10] - The company had an available borrowing capacity of approximately $697 million [10]

Wall Street analysts expect Merit Medical (MMSI) to post quarterly earnings of $0.75 per share in its upcoming report, which indicates a year-over-year decline of 2.6%. Revenues are expected to be $352.33 million, up 8.9% from the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead o ...

Merit Medical Systems, Inc. (MMSI) recently announced the launch of its new Ventrax Delivery System, designed to enhance precision and control in pulmonary interventions. This latest innovation reflects the company’s ongoing commitment to improving procedural efficiency and outcomes in interventional medicine.With the Ventrax Delivery System, Merit Medical expands its growing electrophysiology and cardiac rhythm management (CRM) portfolio. The system integrates seamlessly with existing tools, aiming to addr ...

Merit Medical (MMSI) shares soared 8.3% in the last trading session to close at $95.79. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.1% loss over the past four weeks.The upside can be attributed to relief-rally across global markets following the announcement of a 90-day pause on tariff hike by the United States.This maker of disposable medical devices is expected to post quarterly earnings of $0.75 per share in its upcomin ...

SOUTH JORDAN, Utah, April 09, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader in healthcare technology, today announced the US commercial release of its Ventrax Delivery System. The new delivery system is Merit's latest addition to its growing electrophysiology (EP) and cardiac rhythm management (CRM) portfolio. The portfolio provides a unique selection of solutions to improve cardiac interventions, including the HeartSpan®, Worley™, Prelude SNAP™, and SafeGuard Focus® pr ...

Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardiaSOUTH JORDAN, Utah, April 09, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced the US commercial release of its Ventrax Delivery System. The new delivery system is Merit’s latest addition to its growing electrophysiology (EP) and cardiac rhythm management (CRM) portfolio. The portfolio provides a unique selection of s ...

SOUTH JORDAN, Utah, April 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2025, after the close of the stock market on Thursday, April 24, 2025. Merit plans to hold its investor conference call on the same day (Thursday, April 24, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To acc ...

Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms.SOUTH JORDAN, Utah, March 27, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the American Society for Gastrointestinal Endoscopy (ASGE) updated its guideline on the diagnosis and management of gastroesophageal reflux disease (GERD) to include Transoral Incisionless Fundoplication (TIF 2.0) and TIF 2.0 Consecutive Transo ...